GRTS Gritstone bio Inc

Price (delayed)

$0.589

Market cap

$69.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$119.89M

Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, ...

Highlights
The EPS is up by 13% year-on-year and by 12% since the previous quarter
The net income is up by 8% since the previous quarter
The equity has dropped by 80% year-on-year but it has surged by 59% since the previous quarter
GRTS's quick ratio has dropped by 55% year-on-year but it is up by 29% since the previous quarter
Gritstone bio's debt has increased by 7% YoY

Key stats

What are the main financial stats of GRTS
Market
Shares outstanding
118.11M
Market cap
$69.57M
Enterprise value
$119.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.88
Price to sales (P/S)
5.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.21
Earnings
Revenue
$14.61M
EBIT
-$128.22M
EBITDA
-$107.08M
Free cash flow
-$112.43M
Per share
EPS
-$1.09
Free cash flow per share
-$0.78
Book value per share
$0.2
Revenue per share
$0.1
TBVPS
$0.99
Balance sheet
Total assets
$142.54M
Total liabilities
$120.35M
Debt
$102.49M
Equity
$22.19M
Working capital
$36.81M
Liquidity
Debt to equity
4.62
Current ratio
2.54
Quick ratio
2.38
Net debt/EBITDA
-0.47
Margins
EBITDA margin
-732.9%
Gross margin
100%
Net margin
-910.5%
Operating margin
-934%
Efficiency
Return on assets
-82.5%
Return on equity
-328.5%
Return on invested capital
-67.6%
Return on capital employed
-108.1%
Return on sales
-877.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GRTS stock price

How has the Gritstone bio stock price performed over time
Intraday
5.14%
1 week
19.72%
1 month
17.78%
1 year
-58.23%
YTD
-71.13%
QTD
-4.68%

Financial performance

How have Gritstone bio's revenue and profit performed over time
Revenue
$14.61M
Gross profit
$14.61M
Operating income
-$136.47M
Net income
-$133.03M
Gross margin
100%
Net margin
-910.5%
The revenue has grown by 25% YoY but it has contracted by 7% from the previous quarter
GRTS's gross profit is up by 25% YoY but it is down by 7% QoQ
The company's operating margin rose by 18% YoY
Gritstone bio's net margin has increased by 18% YoY

Growth

What is Gritstone bio's growth rate over time

Valuation

What is Gritstone bio stock price valuation
P/E
N/A
P/B
2.88
P/S
5.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.21
The EPS is up by 13% year-on-year and by 12% since the previous quarter
The equity has dropped by 80% year-on-year but it has surged by 59% since the previous quarter
GRTS's P/B is 59% below its last 4 quarters average of 6.7 and 6% below its 5-year quarterly average of 2.9
The stock's price to sales (P/S) is 80% less than its 5-year quarterly average of 27.6 and 63% less than its last 4 quarters average of 14.8
The revenue has grown by 25% YoY but it has contracted by 7% from the previous quarter

Efficiency

How efficient is Gritstone bio business performance
The ROE has declined by 41% since the previous quarter
Gritstone bio's ROA has decreased by 39% YoY and by 3.1% from the previous quarter
The return on sales is up by 20% year-on-year and by 2.2% since the previous quarter

Dividends

What is GRTS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRTS.

Financial health

How did Gritstone bio financials performed over time
The company's total assets is 18% higher than its total liabilities
GRTS's quick ratio has dropped by 55% year-on-year but it is up by 29% since the previous quarter
Gritstone bio's current ratio has plunged by 54% YoY but it has increased by 27% from the previous quarter
The equity has dropped by 80% year-on-year but it has surged by 59% since the previous quarter
Gritstone bio's debt to equity has decreased by 38% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.